The Top 5 Biosimilar Articles for the Week of June 10

Number 5: Researchers reviewed real-world evidence on the safety and effectiveness of switching from tumor necrosis factor-α inhibitor originators to biosimilars in inflammatory bowel disease (IBD), prompted by mandatory switching policies in most Canadian provinces.

Number 4: Posters from the American Society of Clinical Oncology (ASCO) 2024 annual meeting demonstrate positive safety and efficacy data for denosumab and pegfilgrastim biosimilars.

Number 3: American and European regulatory agencies have provided companies with good news, with several biosimilar candidates seeing application acceptances or approvals in Europe.

Number 2: Sarfaraz K. Niazi, PhD, analyzes updates to the FDA's Biosimilars Action Plan, as well as the agency's increased efforts to boost biosimilar adoption and education.

Number 1: The Biosimilars Council, part of the Association for Accessible Medicines, published a position paper advocating for updates to the FDA's regulatory process for biosimilars. The proposed changes aim to eliminate unnecessary regulatory requirements when no clinical difference exists between a biosimilar and its reference product.

To read all of these articles and more, visit centerforbiosimilars.com.